摘要
药物性肝损伤(drug-induced liver injury,DILI)因其临床特征和病理表现的多样性,尤其是与自身免疫性肝炎(autoimmune hepatitis,AIH)的病理学重叠,给诊断和治疗带来了巨大挑战。本文对DILI的临床转归及相关影响因素展开阐述,并探讨了实验室指标、影像学和病理学评估在诊疗中的应用与局限性,并提出了可能转变为AIH的高风险患者的早期识别和管理策略,为DILI的精准诊断与个性化治疗提供科学依据。
Drug-induced liver injury(DILI)presents a significant diagnostic and therapeutic challenge due to its diverse clinical features and pathological manifestations,especially its overlap with autoimmune hepatitis(AIH).This article reviewed the clinical outcomes of DILI and the associated influencing factors,explored the application and limitations of laboratory indicators,imaging,and pathological assessments in diagnosis and treatment,and proposes early identification and management strategies for high-risk patients who might progress to AIH.These insights aim to provide a scientific basis for the precise diagnosis and personalized treatment of DILI.
作者
师安怡
孙磊
邢卉春
Shi Anyi;Sun Lei;Xing Huichun(Center of Liver Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《中国医学前沿杂志(电子版)》
北大核心
2025年第6期34-39,共6页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
北京市科技计划(Z221100007422002)
首都卫生发展科研专项(首发2024-1v2181)
肝胆相照公益基金(iGandaF-1082023-GSH011)。
